Volume 89 Issue 37 | p. 13 | Concentrates
Issue Date: September 12, 2011

Anacor Extends R&D Deals

Department: Business
News Channels: Biological SCENE
Keywords: boron chemistry, pharmaceuticals, malaria, antibiotics

Anacor Pharmaceuticals has expanded R&D collaborations for its boron-based anti-infective agents. GlaxoSmithKline now has the option to obtain rights related to the bacterial enzyme target leucyl-tRNA synthetase and to add programs for tuberculosis and malaria. In return, Anacor will receive $5.0 million up front and R&D and milestone payments of up to $11.3 million through 2012. Separately, the U.S. government just granted GSK up to $94 million to support, among other things, the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society